Skip Navigation



European Heart Journal Advance Access published online on January 6, 2006
European Heart Journal, doi:10.1093/eurheartj/ehi705
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
27/10/1153    most recent
ehi705v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gislason, G. H.
Right arrow Articles by Torp-Pedersen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gislason, G. H.
Right arrow Articles by Torp-Pedersen, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal © The European Society of Cardiology 2005; all rights reserved
Received October 10, 2005
Revised December 5, 2005
Accepted December 8, 2005

Clinical research

Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction

Gunnar H. Gislason 1 *, Jeppe N. Rasmussen 2, Steen Z. Abildstrøm 3, Niels Gadsbøll 4, Pernille Buch 1, Jens Friberg 5, Søren Rasmussen 2, Lars Køber 6, Steen Stender 7, Mette Madsen 2, and Christian Torp-Pedersen 5

1 Department of Cardiovascular Medicine, Bispebjerg University Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark; National Institute of Public Health, Copenhagen, Denmark
2 National Institute of Public Health, Copenhagen, Denmark
3 National Institute of Public Health, Copenhagen, Denmark; Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark
4 Department of Internal Medicine, Roskilde County Hospital, Roskilde, Denmark
5 Department of Cardiovascular Medicine, Bispebjerg University Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark
6 Department of Cardiology, The Heart Centre, Rigshospitalet--National University Hospital, Copenhagen, Denmark
7 Clinical Biochemistry, Gentofte University Hospital, Hellerup, Denmark

* To whom correspondence should be addressed.
Gunnar H. Gislason, E-mail: gg{at}heart.dk


  Abstract

Aims To study initiation, dosages, and compliance with beta-blockers, angiotensin-converting enzyme (ACE)-inhibitors, and statins in patients after acute myocardial infarction (AMI) and to identify likely targets for improvement.

Methods and results Patients admitted with first AMI between 1995 and 2002 were identified by linking nationwide administrative registers. A total of 55 315 patients survived 30 days after discharge and were included; 58.3% received beta-blockers, 29.1% ACE-inhibitors, and 33.5% statins. After 1, 3, and 5 years, 78, 64, and 58% of survivors who had started therapy were still receiving beta-blockers, 86, 78, and 74% were receiving ACE-inhibitors, and 85, 80, and 82% were receiving statins, respectively. Increased age and female sex were associated with improved compliance. The dosages prescribed were generally 50% or less of the dosages used in clinical trials, and dosages did not increase during the observation period. Patients who did not start treatment shortly after discharge had a low probability of starting treatment later.

Conclusion The main problem with underuse of recommended treatment after AMI is that treatment is not initiated at an appropriate dosage shortly after AMI. A focused effort in the immediate post-infarction period would appear to provide long-term benefit.

Keywords: Acute myocardial infarction; Beta-blockers; ACE-inhibitors; Statins; Pharmacological treatment; Compliance.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
K. Swedberg, M. Komajda, M. Bohm, J. S. Borer, I. Ford, and L. Tavazzi
Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT)
Eur J Heart Fail, November 5, 2009; (2009) hfp154v1.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
K. Fox, I. Ford, Ph. G. Steg, M. Tendera, M. Robertson, R. Ferrari, and on behalf of the BEAUTIFUL Investigators
Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
Eur. Heart J., October 1, 2009; 30(19): 2337 - 2345.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
Z. Bagi
Mechanisms of coronary microvascular adaptation to obesity
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2009; 297(3): R556 - R567.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J.-C. Tardif, P. Ponikowski, T. Kahan, and for the ASSOCIATE study Investigators
Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial
Eur. Heart J., March 1, 2009; 30(5): 540 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. Sajadieh
A new combination therapy in stable angina pectoris
Eur. Heart J., March 1, 2009; 30(5): 524 - 525.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
G. H. Gislason, J. N. Rasmussen, S. Z. Abildstrom, T. K. Schramm, M. L. Hansen, E. L. Fosbol, R. Sorensen, F. Folke, P. Buch, N. Gadsboll, et al.
Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure
Arch Intern Med, January 26, 2009; 169(2): 141 - 149.
[Abstract] [Full Text] [PDF]

Home page
 J. Epidemiol. Community HealthHome page
J. N Rasmussen, G. H Gislason, S. Rasmussen, S. Z Abildstrom, T. K Schramm, L. Kober, F. Diderichsen, M. Osler, C. Torp-Pedersen, and M. Madsen
Use of statins and beta-blockers after acute myocardial infarction according to income and education
J Epidemiol Community Health, December 1, 2007; 61(12): 1091 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Bangalore, F. H. Messerli, J. B. Kostis, and C. J. Pepine
Cardiovascular Protection Using Beta-Blockers: A Critical Review of the Evidence
J. Am. Coll. Cardiol., August 14, 2007; 50(7): 563 - 572.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. H. Gislason, J. N. Rasmussen, S. Z. Abildstrom, T. K. Schramm, M. L. Hansen, P. Buch, R. Sorensen, F. Folke, N. Gadsboll, S. Rasmussen, et al.
Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes
Circulation, August 14, 2007; 116(7): 737 - 744.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. N. Rasmussen, A. Chong, and D. A. Alter
Relationship Between Adherence to Evidence-Based Pharmacotherapy and Long-term Mortality After Acute Myocardial Infarction
JAMA, January 10, 2007; 297(2): 177 - 186.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. H. Gislason, S. Jacobsen, J. N. Rasmussen, S. Rasmussen, P. Buch, J. Friberg, T. K. Schramm, S. Z. Abildstrom, L. Kober, M. Madsen, et al.
Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction
Circulation, June 27, 2006; 113(25): 2906 - 2913.
[Abstract] [Full Text] [PDF]

Home page
 Journal Watch CardiologyHome page
Post-MI Therapies: Initiation and Adherence
Journal Watch Cardiology, June 8, 2006; 2006(608): 4 - 4.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.